Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Franz Prager

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Journal of Cataract and Refractive Surgery|April 4, 2017
Intraindividual comparison of capsule behavior of 2 hydrophobic acrylic intraocular lenses during a 5-year follow-upGuenal Kahraman, Clara Ferdinaro, Barbara Wetzel, et al.
Retina (Philadelphia, Pa.)|October 13, 2006
Evaluation of anterior chamber inflammatory activity in eyes treated with intravitreal bevacizumabChristopher Kiss, Stephan Michels, Franz Prager, et al.
European Journal of Ophthalmology|July 14, 2016
Regression of epiretinal membrane after optic nerve atrophyBarbara Wetzel, Georgios Mylonas, Franz Prager, et al.
Ophthalmology|September 12, 2009
Association of retinal sensitivity and morphology during antiangiogenic treatment of retinal vein occlusion over one yearKatharina Kriechbaum, Franz Prager, Wolfgang Geitzenauer, et al.
American Journal of Ophthalmology|October 6, 2007
Intravitreal bevacizumab therapy for neovascular age-related macular degeneration with large submacular hemorrhageEva Stifter, Stephan Michels, Franz Prager, et al.
Acta Ophthalmologica|June 3, 2009
Effect of intravitreal bevacizumab (Avastin) in neovascular age-related macular degeneration using a treatment regimen based on optical coherence tomography: 6- and 12-month resultsChristina Leydolt, Stephan Michels, Franz Prager, et al.
Retina (Philadelphia, Pa.)|September 12, 2008
Comparison of 2.5 mg/kg and 5 mg/kg systemic bevacizumab in neovascular age-related macular degeneration: twenty-four week results of an uncontrolled, prospective cohort studyWolfgang Geitzenauer, Stephan Michels, Franz Prager, et al.
Investigative Ophthalmology & Visual Science|December 9, 2008
Intraocular concentrations of growth factors and cytokines in retinal vein occlusion and the effect of therapy with bevacizumabMarion Funk, Katharina Kriechbaum, Franz Prager, et al.
Graefe'S Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie|December 4, 2012
Effects of orally administered moxaverine on ocular blood flow in healthy subjectsDoreen Schmidl, Berthold Pemp, Michael Lasta, et al.
Investigative Ophthalmology & Visual Science|October 3, 2009
Imaging of the retinal pigment epithelium in age-related macular degeneration using polarization-sensitive optical coherence tomographyChristian Ahlers, Erich Götzinger, Michael Pircher, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Journal of Cataract and Refractive Surgery|April 4, 2017
Intraindividual comparison of capsule behavior of 2 hydrophobic acrylic intraocular lenses during a 5-year follow-upGuenal Kahraman, Clara Ferdinaro, Barbara Wetzel, et al.
Retina (Philadelphia, Pa.)|October 13, 2006
Evaluation of anterior chamber inflammatory activity in eyes treated with intravitreal bevacizumabChristopher Kiss, Stephan Michels, Franz Prager, et al.
European Journal of Ophthalmology|July 14, 2016
Regression of epiretinal membrane after optic nerve atrophyBarbara Wetzel, Georgios Mylonas, Franz Prager, et al.
Ophthalmology|September 12, 2009
Association of retinal sensitivity and morphology during antiangiogenic treatment of retinal vein occlusion over one yearKatharina Kriechbaum, Franz Prager, Wolfgang Geitzenauer, et al.
American Journal of Ophthalmology|October 6, 2007
Intravitreal bevacizumab therapy for neovascular age-related macular degeneration with large submacular hemorrhageEva Stifter, Stephan Michels, Franz Prager, et al.
Acta Ophthalmologica|June 3, 2009
Effect of intravitreal bevacizumab (Avastin) in neovascular age-related macular degeneration using a treatment regimen based on optical coherence tomography: 6- and 12-month resultsChristina Leydolt, Stephan Michels, Franz Prager, et al.
Retina (Philadelphia, Pa.)|September 12, 2008
Comparison of 2.5 mg/kg and 5 mg/kg systemic bevacizumab in neovascular age-related macular degeneration: twenty-four week results of an uncontrolled, prospective cohort studyWolfgang Geitzenauer, Stephan Michels, Franz Prager, et al.
Investigative Ophthalmology & Visual Science|December 9, 2008
Intraocular concentrations of growth factors and cytokines in retinal vein occlusion and the effect of therapy with bevacizumabMarion Funk, Katharina Kriechbaum, Franz Prager, et al.
Graefe'S Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie|December 4, 2012
Effects of orally administered moxaverine on ocular blood flow in healthy subjectsDoreen Schmidl, Berthold Pemp, Michael Lasta, et al.
Investigative Ophthalmology & Visual Science|October 3, 2009
Imaging of the retinal pigment epithelium in age-related macular degeneration using polarization-sensitive optical coherence tomographyChristian Ahlers, Erich Götzinger, Michael Pircher, et al.
Pageof 3